The identities of enzymes: study further defines the function of a potential target for Alzheimer’s therapy

A new study from the lab of UW-Madison professor of medicine Luigi Puglielli, MD, PhD, opens a door to potential treatments for diseases of age, such as Alzheimer’s disease, by defining the roles of two enzymes that are imperative to protein production.

New NIH-funded initiative will examine Alzheimer’s disease in people with Down syndrome

A team of researchers at the University of Wisconsin–Madison is part of a new multi-institution effort to better understand Alzheimer’s disease in adults with Down syndrome. Adults with Down syndrome are at high risk for …

Mancheski Foundation funds next-gen research on Down syndrome and Alzheimer’s

A gift from the Mancheski Foundation continues to provide integral support to doctoral student Matthew Zammit as he furthers his research on the progression of Alzheimer’s disease in individuals with Down syndrome. Zammit is beginning …

In Wisconsin, 3 in 5 people with Down syndrome diagnosed with dementia by age 55

Not so many years ago, people with Down syndrome rarely survived to middle age. Many died young due to heart problems associated with the congenital condition.
Today, advances in treatment have allowed them to live longer, healthier lives.

UW-Madison biomanufacturer offers essential gene-transfer capacity

Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the Waisman lab’s growing importance in the biopharma business, as it’s the only facility on campus meeting FDA “good manufacturing practices” rules for large-scale manufacturing of biological therapies.